AnaptysBio News and Activities

AnaptysBio is owned by Sagard Holdings. Sagard Holdings has a direct presence in 4 countries.

Sagard Holdings has 11 subsidiaries including Acheel, Achieve and ADIT.

They are in:

• Insurance25%
• Financial Services17%
• Other58%

View the org chart displaying its 37 main executives

Most searched biographies at AnaptysBio

• Daniel Faga, President and Chief Executive Officer
• Oleg Nodelman, Director
• Dennis Mulroy, Director

Popular executive movements at AnaptysBio

• Chris Murphy has joined the company as Chief Financial Officer  (posted on May 12 2026).
• Dennis Mulroy who was Chief Financial Officer, becomes Director  (posted on May 12 2026).

Popular executive movements at Sagard Holdings

• Kris Hansen, Chief Technology Officer, has left the company  (posted on January 5 2026).

Create your alert
to follow the executive moves at AnaptysBio.

Sagard Holdings has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by AnaptysBio

• Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update | AnaptysBio, Inc.
• Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors | AnaptysBio, Inc.
• Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference | AnaptysBio, Inc.
• Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim | AnaptysBio, Inc.
• Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations | AnaptysBio, Inc.
• Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics | AnaptysBio, Inc.
• First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement | AnaptysBio, Inc.
• Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update | AnaptysBio, Inc.
• Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results | AnaptysBio, Inc.
• Anaptys Announces Participation at Upcoming Investor Conferences | AnaptysBio, Inc.
• View more press releases Close

Social media about AnaptysBio

• AnaptysBio on Wikipedia, Google News & Yahoo Finance
• AnaptysBio on LinkedIn, X (Twitter) & YouTube